Business Context and Reporting Period
This Form 8-K filing by Bionano Genomics, Inc. (BNGO) reports a current event dated December 31, 2020. The Company is an emerging growth company incorporated in Delaware with principal executive offices in San Diego, California. Its common stock and warrants trade on The Nasdaq Stock Market, LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt balances, or liquidity ratios. The report focuses exclusively on a covenant compliance matter rather than presenting a full financial statement.
Material Changes and Events
- Covenant Waiver: On December 31, 2020, the Company obtained a waiver from Innovatus Life Sciences Lending Fund I, LP ("Innovatus").
- Reason for Waiver: The waiver addressed a previously disclosed noncompliance with a revenue covenant as of September 30, 2020.
- Underlying Agreement: The covenant is contained in the Loan and Security Agreement dated March 14, 2019, among the Company, Innovatus, and East West Bank, as amended.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of new risks. The primary contingency addressed was the potential default on the revenue covenant, which was resolved via the waiver obtained on the reporting date.
Investor Verification Checklist
- Verify the terms of the revenue covenant in the March 14, 2019 Loan and Security Agreement to understand the specific threshold missed as of September 30, 2020.
- Confirm whether the waiver from Innovatus includes any new conditions, fees, or amendments to the loan agreement.
- Review the Company's subsequent financial reports (e.g., 10-K or 10-Q) to assess if revenue targets were met in the following periods.
- Check for any other outstanding covenants with East West Bank or Innovatus that may be at risk of noncompliance.